Find activities

122 results

  • MSAC Consultation Survey - Application 1822

    MSAC application 1822 F-18 Fluorodeoxyglucose (FDG) positron emission tomography (PET) for evaluation of complex infection. Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a proposed health service or technology fits in the Australian... More
    Opened 25 September 2026

  • MSAC Consultation Survey - Application 1831

    MSAC Application 1831 Kappa free-light chain (kFLC) index testing for the diagnosis of multiple sclerosis (MS). Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a proposed health service or technology fits in the Australian health care ... More
    Opened 25 September 2026

  • MSAC Consultation Survey - Application 1832

    MSAC Application 1832 Detection of measurable residual disease (MRD) in patients with multiple myeloma (MM). Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a proposed health service or technology fits in the Australian health care ... More
    Opened 25 September 2026

  • MSAC Consultation Survey - Application 1830

    MSAC application 1830 Genetic testing to identify homologous recombination repair (HRR) gene alterations in patients with metastatic castration-sensitive prostate cancer (mCSPC) to determine eligibility for treatment with PBS subsidised talazoparib. Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation... More
    Opened 25 September 2026

  • MSAC Consultation Survey - Application 1829

    MSAC application 1829 Anti-Müllerian hormone testing for identification of Polycystic Ovarian Morphology, to support the diagnosis of Polyendrocrine Metabolic Ovarian Syndrome (PMOS). Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a... More
    Opened 25 September 2026

  • MSAC Consultation Survey - Application 1828

    MSAC application 1828 Review of devices used in catheter-based cardiac ablation for the treatment of patients with cardiac arrhythmias. Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a proposed health service or technology fits in the... More
    Opened 25 September 2026

  • MSAC Consultation Survey - Application 1629.1

    MSAC Application 1629.1 Defensive Antibacterial Coating (DAC) with antibiotics for reducing the risk of periprosthetic surgical site infection. Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a proposed health service or technology... More
    Opened 25 September 2026

  • MSAC Consultation Survey - Application 1835

    MSAC Application 1835 Lifileucel for the treatment of patients with previously treated unresectable or metastatic melanoma. Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a proposed health service or technology fits in the Australian... More
    Opened 25 September 2026

  • MSAC Consultation Survey - Application 1834

    MSAC Application 1834 Efanesoctocog alfa for routine prophylaxis in patients with haemophilia A. Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a proposed health service or technology fits in the Australian health care environment. It... More
    Opened 25 September 2026

  • Public consultation on GOSERELIN - Zoladex® for the proposed treatment of hormone receptor-positive breast cancer to be considered by the PBAC (Sept 2026) Intracycle Meeting

    The agenda for the September 2026 Pharmaceutical Benefits Advisory Committee (PBAC) meeting is now available. Information about each item can also be found on the Medicine Status Website (from 1 September 2026). Consultation is open for Zoladex® 10.8 mg Implant (goserelin) for the proposed treatment of hormone receptor-positive breast cancer. The consultation period is shorter than usual to enable input to be considered at the September 2026 PBAC meeting. The PBAC... More
    Opened 28 August 2026

  • Public consultation survey for the Rapid Review of PBS medicines for relapsing-remitting multiple sclerosis (RRMS) (December 2026 PBAC meeting)

    Consultation is now open for the rapid review of Pharmaceutical Benefits Scheme (PBS) medicines for relapsing-remitting multiple sclerosis (RRMS). For further information on the review including background, processes, timelines and guiding research questions, please refer to the RRMS review website . The PBAC welcomes input from patients, carers, health professionals, consumer groups or organisations and members of the public. Input can be submitted... More
    Opened 20 August 2026

  • MSAC Consultation Survey - Application 1695

    MSAC Application 1695 Procedures for the implantation and refill-exchange of the Port Delivery System with ranibizumab to treat neovascular age-related macular degeneration. Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a proposed... More
    Opened 29 July 2026

  • Public consultation on items to be considered by the PBAC (November 2026)

    Consultation has opened for the November 2026 Pharmaceutical Benefits Advisory Committee (PBAC) agenda. The PBAC welcomes input from patients, carers, health professionals, consumer groups or organisations and members of the public on medicines and vaccines submitted for PBAC consideration. The PBAC considers these public consultation inputs when considering the clinical and economic evidence presented by the applicant. Information provided by consumers helps the committee... More
    Opened 22 July 2026

  • 1754 - Surgical Procedures for Gender Affirmation in Adults with Gender Incongruence - resubmission

    A further period of consultation is open on application 1754 – Surgical Procedures for Gender Affirmation in Adults with Gender Incongruence, for consideration by the Medical Services Advisory Committee (MSAC) and its Evaluation Subcommittee (ESC). Consultation input helps MSAC and its subcommittees to better understand how a proposed health service or technology fits in the Australian health care environment. Background MSAC application 1754 is progressing via a... More
    Opened 24 June 2026

  • MSAC Consultation Survey - Application 1819

    MSAC application 1819 Breyanzi (lisocabtagene maraleucel) for the treatment of large B-cell lymphoma. Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a proposed health service or technology fits in the Australian health care ... More
    Opened 24 June 2026

  • MSAC Consultation Survey - Application 1803

    MSAC application 1803 - Implantation of an active middle ear implant (Vibroplasty) for treatment of mixed and conductive hearing loss. Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a proposed health service or technology fits in the... More
    Opened 24 June 2026

  • MSAC Consultation Survey - Application 1802

    MSAC application 1802 - Supervised oral food challenge (OFC) in patients with suspected food allergy. Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a proposed health service or technology fits in the Australian health care ... More
    Opened 24 June 2026

  • MSAC Consultation Survey - Application 1810

    MSAC application 1810 Genomic testing for the diagnosis of primary immunodeficiency (PID). Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a proposed health service or technology fits in the Australian health care environment. It does... More
    Opened 24 June 2026

  • Feedback on consumer input

    We are seeking your views on how consumers and consumer organisations should receive feedback after they provide input on HTA committee agenda items. The Office of Health Technology Assessment’s (OHTA) Consumer Evidence and Engagement Unit (CEEU) is exploring practical ways to give clear and consistent feedback to consumers and consumer organisations about how their input was used during the health technology assessment (HTA) process and in HTA committee... More
    Opened 16 June 2026

  • EOI for feedback on consumer input

    The Office of Health Technology Assessment’s (OHTA) Consumer Evidence and Engagement Unit (CEEU) is exploring practical ways to provide consumers and consumer organisations with clear and consistent feedback about how their input is used in health technology assessment (HTA) processes and in HTA committee discussions. As part of this work, we are conducting an online survey and having virtual conversations with consumer organisations that will focus on: ... More
    Opened 15 June 2026

  • MSAC Consultation Survey - Application 1823

    MSAC application 1823 177 Lutetium PSMA-617 for prostate specific membrane antigen (PSMA)-positive, taxane-naïve patients with metastatic castrate resistant prostate cancer (mCRPC). Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a... More
    Opened 29 May 2026

  • MSAC Consultation Survey - Application 1825

    MSAC application 1825 Transcranial Doppler bubble test for patent foramen ovale. Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a proposed health service or technology fits in the Australian health care environment. It does this by... More
    Opened 29 May 2026

  • MSAC Consultation Survey - Application 1821

    MSAC application 1821 Testing for Chromogranin A in patients with neuroendocrine neoplasms. Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a proposed health service or technology fits in the Australian health care environment. It... More
    Opened 29 May 2026

  • MSAC Consultation Survey - Application 1826

    MSAC application 1826 N-Terminal-pro Brain Natriuretic Peptide (NT-proBNP) testing to support management of patients with heart failure. Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a proposed health service or technology fits in the... More
    Opened 29 May 2026

  • MSAC Consultation Survey - Application 1820

    MSAC application 1820 In situ hybridisation (ISH) testing of tumour tissue to detect viral genomes (EBV and HPV). Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a proposed health service or technology fits in the Australian health... More
    Opened 29 May 2026

  • MSAC Consultation Survey - Application 1738.1

    MSAC application 1738.1 Investigations to support the use of PBS subsidised lecanemab in people with mild cognitive impairment and mild dementia due to Alzheimer’s disease. Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a proposed... More
    Opened 29 May 2026

  • MSAC Consultation Survey - Application 1827

    MSAC application 1827 Testing for hepatitis B virus (HBV) and hepatitis B virus surface antigen (HBsAg) to support the use of PBS subsidised bepirovirsen in people with chronic hepatitis B (CHB). Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better... More
    Opened 29 May 2026

  • Framework for consumer engagement in HTA

    We are developing a framework that sets out guiding principles, focus areas and actions to support better consumer engagement in HTA. We'd like to hear your thoughts on the framework and how it could be improved. We will summarise your responses and share the findings so you can see what we heard and how we used the feedback to improve the framework. If you have difficulty responding online, please email htaconsumerengagement@health.gov.au . View the... More
    Opened 28 April 2026

  • MSAC Consultation Survey - Application 1818

    MSAC Application 1818 – Expansion of specialist supervision criteria for MBS and PBS items for integrated, closed-system, extracorporeal photopheresis and methoxsalen (UVADEX®) for the treatment of Cutaneous T-Cell Lymphoma and chronic Graft Versus Host Disease. Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). ... More
    Opened 1 April 2026

  • Public consultation on items to be considered by the PBAC (July 2026)

    Consultation has opened for the July 2026 Pharmaceutical Benefits Advisory Committee (PBAC) agenda. The PBAC welcomes input from patients, carers, health professionals, consumer groups or organisations and members of the public on medicines and vaccines submitted for PBAC consideration. The PBAC considers these public consultation inputs when considering the clinical and economic evidence presented by the applicant. Information provided by consumers helps the committee... More
    Opened 25 March 2026
122 results. Page 1 of 5